A2 Biotherapeutics is thrilled to announce a significant funding milestone of $80 million, a strategic investment that will expedite the company’s mission to revolutionize cancer treatment through innovative cell therapy. Founded in 2018 by visionary leaders Alexander Kamb, Michael Gallo, and Paul Kang, A2 is dedicated to transforming medicine by targeting solid tumors—a challenging frontier in the field. The latest funding round, which brings the total capital raised since inception to an impressive $136 million, comes from a consortium of esteemed investors, including The Column Group, Vida Ventures, and Hartford HealthCare Endowment. This financial boost will facilitate the advancement of A2's cutting-edge technology that engineers T cells to specifically recognize and attack tumor cells that have lost crucial genetic material, thereby enabling rapid and selective destruction of malignant cells while sparing healthy tissues. The implications of this innovative approach hold tremendous promise for patients facing daunting cancer diagnoses. With this new infusion of funds, A2 aims to accelerate clinical development, enhance research capabilities, and expand its team of experts dedicated to making a tangible impact in oncology. “This investment validates our approach and underscores the confidence our investors have in our vision to tackle the complexities of solid tumors,” said CEO Alexander Kamb. A2 Biotherapeutics epitomizes the future of personalized medicine, and with substantial resources backing its quest, the company is poised to break new ground in the fight against cancer.
Revolutionizing Cancer Treatment: A2 Biotherapeutics Secures $80M in Series C Funding
Get the full A2 Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Synthetic
We deliver systems, devices and applications that combine the mobility of IoT with the practicality of artificial intelligence. Focusing on high availability connectivity. Our core is based on modular and scalable products for hardware and software solutions.
$10.0M Seed
today
SonoMind
Sonomind is a medical device company specializing in non-invasive brain stimulation utilizing low-intensity focused ultrasound to treat drug-resistant depression and other neurological and psychiatric conditions. This portable device is the first to deliver precision transcranial ultrasound stimulation that is able to penetrate deep brain structures in an accurate, targeted and non-invasive manner. A custom-designed acoustic lens for each patient delivers low-intensity focused ultrasound, enabling ultrasound waves to pass through the skull and compensate for any distortion upon entering the brain. Located in Paris, France, Sonomind has a staff of ten, headed by CEO Jeremy Bercoff. The company leverages 25 years of research undertaken by Profs. Mickael Tanter and Jean-François Aubry at the Institut Physique pour la Médecine (Inserm, ESPCI Paris - PSL, CNRS). Sonomind has raised €2 million since inception
$23.5M Series a
today
.png&w=3840&q=75)
harva. (formerly Supply Pay)
We build the operating system for perishables companies. One platform for inventory, sales, accounting, and embedded financing powered by AI, built for the way perishables actually works. Formerly Supply Pay Inc.
$113.0M Seed
today
Rivermark Medical, Inc.
Minimally Invasive Device Therapy for BPH
$20.0M Series d
today
DDD Invoices - One API, global invoicing compliance
DDD Invoices powers global invoicing compliance in 30+ countries, with a special focus on Central & Eastern Europe. We help SaaS, ERP/POS, PMS, marketplaces, and payment providers integrate mandatory e-invoicing in days — turning compliance from a burden into a competitive advantage. Mandatory e-invoicing is expanding fast — and no company can afford to fall behind. At DDD Invoices, we help software providers embed multi-country e-invoicing and fiscalization directly into their products — in days, not months. With one API, you get: → Compliance in 30+ countries worldwide — including full coverage of CEE mandates (Poland KSeF, Hungary NAV, Romania RO_Cius, Serbia SEF, Croatia Fiscalization 2.0, Montenegro, and more). → Fastest go-live — integrate in days, not months. → Built-in expertise & updates — we track local regulations so you don’t have to. → Monetization potential — turn compliance into a feature your clients will pay for. For ambitious software providers, mandatory e-invoicing is not just a regulatory hurdle — it’s a growth opportunity. DISCOVERY CALL https://calendly.com/ddd-invoices/45min FREE TRIAL https://dddinvoices.com/platform-e-invoicing-invoicing-fiscalization-api LIVE Q&A SESSION, Oct 8 Register on Luma to attend: https://lu.ma/aqtmqw36
$1.5M Seed
today
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Yabie Sweden | Series c | $26.2M | 2d ago |
| 2 |  Trevi Therapeutics, Inc. United States | Series c | $50.5M | 2d ago |
| 3 |  Freyja Healthcare | Series c | $20.5M | 2d ago |
| 4 |  NuCurrent United States | Series c | $100.0K | 2d ago |
| 5 |  PlusAI United States | Series c | $220.0M | 2d ago |